New Risk • Aug 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$297m Forecast net loss in 3 years: US$73m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (42% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.4m sold). Live News • Aug 15
FDA Approves TUDRIQEV Combo as Replimune Secures Funding and Appoints Commercial Chief Replimune Group reported that TUDRIQEV, in combination with nivolumab, has received accelerated approval from the FDA, with a commercial launch targeted within 60 days, and the company has completed financing to fund the launch and the ongoing confirmatory trial.
The company appointed Michelle DiNapoli as Chief Commercial Officer to lead commercialization of TUDRIQEV, indicating a build-out of its commercial infrastructure alongside the regulatory milestone.
Replimune’s share price is US$14.97, with the stock up 186.8% over the past 90 days.
This combination of first product approval, commercial leadership hire and new funding moves Replimune toward a commercial-stage profile and ties its outlook more closely to execution on the TUDRIQEV launch and the required confirmatory study. Announcement • Aug 14
Replimune Group, Inc. Announces Appointment of Michelle Dinapoli to Chief Commercial Officer, Effective August 18, 2026 Replimune Group, Inc. announced the appointment of Michelle DiNapoli as Chief Commercial Officer, effective August 18, 2026. Michelle DiNapoli brings more than 25 years of biopharmaceutical experience commercializing innovative oncology therapies and building high-performing commercial organizations. She joins Replimune after a seven-year tenure at Deciphera Pharmaceuticals. At Deciphera, she built the U.S. sales force, led the U.S. Commercial organization, and scaled infrastructure to drive launch execution as the company grew from a single product to a multi-product organization. Prior to Deciphera, Ms. DiNapoli spent 16 years at Genentech in commercial leadership roles spanning breast, lung, and colorectal cancer franchises as well as cancer immunotherapy, developing deep expertise in market access, lifecycle management, and cross-functional execution. 
